From: Safety and efficacy of sirolimus in recurrent intravenous leiomyomatosis, pulmonary benign metastatic leiomyomatosis, and leiomyomatosis peritonealis disseminata: a pilot study
Best objective response
No
%
95% CI
ORR
3
20.0
7.1–45.2
DCR
13
86.7
62.1–96.3
PR
SD
10
66.6
41.7–84.8
PD
2
13.3
3.7–37.9